Literature DB >> 3298909

Analgesic effect of actinonin, a new potent inhibitor of multiple enkephalin degrading enzymes.

M Hachisu, T Hiranuma, S Murata, T Aoyagi, H Umezawa.   

Abstract

Actinonin, previously isolated as an antibiotic and shown to be an inhibitor of aminopeptidase M (EC 3.4.11.2), has now been shown to inhibit three enkephalin-degrading enzymes from guinea-pig striatum. The values of IC50 were 0.39 microM for striatal membrane aminopeptidase ("enkephalin-aminopeptidase") and 5.6 microM striatal membrane neutral endopeptidase ("enkephalinase A"). Furthermore, soluble dipeptidylaminopeptidase in a rat whole brain homogenate was also inhibited by actinonin with the IC50 value of 1.1 microM. Actinonin administered intracisternally (i.cist., 50 micrograms) or intraperitoneally (i.p., 100 mg/kg), potentiated the analgesic action of met-enkephalin (50 micrograms i.cist.). analgesia by a tail-flick test. The potentiating activity of actinonin i.p. to met-enkephalin analgesia was almost the same potency as that of thiorphan, whereas the inhibitory activity of actinonin against enkephalinase A was 1/1000 that of thiorphan. Actinonin alone, administered either i.cist. or i.p., showed an analgesic action as estimated by the tail-flick test.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3298909     DOI: 10.1016/0024-3205(87)90498-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Development of high throughput screening assays and pilot screen for inhibitors of metalloproteases meprin α and β.

Authors:  Franck Madoux; Claudia Tredup; Timothy P Spicer; Louis Scampavia; Peter S Chase; Peter S Hodder; Gregg B Fields; Christoph Becker-Pauly; Dmitriy Minond
Journal:  Biopolymers       Date:  2014-09       Impact factor: 2.505

Review 2.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.